Phase II Jastreboff 2023 NEJM : -24,2% a 12mg/48sem pour retatrutide vs SURMOUNT-1 Jastreboff 2022 : -20,9% a 15mg/72sem pour tirzepatide
Tirzepatide, also known by its brand name Monjaro, is another GLP-1 agonist that works similarly to Semaglutide
Methods Using a subset of Truveta Data, we identified patients with any medication dispense (e.g., medication fill) of a GLP-1 RA (semaglutide AOM, semaglutide ADM oral, semaglutide ADM injectable, liraglutide ADM, exenatide ADM, lixisenatide ADM, tirzepatide ADM, and dulaglutide ADM) between January 2018 and October 2023
Disorders of glucose metabolism in PraderWilli syndrome: results of a multicenter Italian cohort study
Semaglutide Weight Loss Treatment in WestHollywood: FAQs How long does it take to see results